Almirall: investors seize stock as EU approves eczema drug

(CercleFinance.com) - Shares in the Spanish pharmaceuticals group Almirall rose sharply in Madrid on Friday, following the announcement that its new treatment for atopic dermatitis (eczema) had been granted marketing authorisation in Europe.


The stock is currently up 5%, streets ahead of the IBEX (+0.6%) and the STOXX Europe 600 Health Care index (+1.2%).

The Barcelona-based laboratory this morning announced that the European Commission has approved Ebglyss (lebrikizumab) for the treatment of adults and adolescents suffering from moderate-to-severe forms of the disease.

In a recent research note, analysts at Royal Bank of Canada forecast annual sales of E159m for Ebglyss (lebrikizumab).

Adding sales of Ilumetri, another Almirall psoriasis treatment, the Group's dermatology franchise should represent total revenues of E327m by 2030, or 60% of annual sales, RBC forecasts.


Copyright (c) 2023 CercleFinance.com. All rights reserved.